PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR
- Conditions
- Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smoker
- Registration Number
- JPRN-UMIN000005491
- Lead Sponsor
- Hiroshima citizens hospital Department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1) Radiotherapy to the primary site which is only possible to evaluate 2) superior vena cava syndrome 3) History of severe drug allergy 4) Uncontrolled pleural effusion, ascites, or pericardial effusion 5) History of active infection 6) Uncontrollable diarrhea 7) History of ileus 8) Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 9) Symptomatic eye disease 10) Current or previous(within the last 1 year) history of GI perforation 11) uncontrollable ulcer 12) Symptomatic brain metastases 13) Other active malignancies 14) History of active double cancer 15) Poorly controlled diabetes mellitus 16) History of severe heart disease 17) History of active psychological disease 18) History of pregnancy or lactation 19) Evaluated to be ineligible by a physician for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rat
- Secondary Outcome Measures
Name Time Method